Biogen (BIIB) Payables (2009 - 2026)
Biogen (BIIB) posted quarterly Payables of $403.9 million for Q2 2026, down 1.1% year-over-year from $408.4 million in Q2 2025, and up 12.66% quarter-over-quarter from $358.5 million in Q1 2026.
Biogen (BIIB) Payables (2009 - 2026) Analysis & Trends
Biogen's Payables history runs 18 years deep, the most recent figure standing at $403.9 million for Q2 2026.
- In Q2 2026, Payables fell 1.1% year-over-year to $403.9 million; the TTM figure through Jun 2026 stood at $403.9 million (down 1.1% YoY), while the FY2025 annual figure was $432.0 million, down 80.12% from the prior year.
- Payables for Q2 2026 stood at $403.9 million, up from $358.5 million in the prior quarter.
- The five-year high for Payables was $2.2 billion in Q4 2024, with the low at $354.5 million in Q2 2024.
- The 5-year median for Payables is $491.4 million (2022), against an average of $868.3 million.
- The sharpest annual moves came in 2024 and 2026: Payables surged 292.7% in 2024, then plunged 83.25% in 2026.
- Biogen's Payables stood at $491.5 million in 2022, then gained by 12.57% to $553.3 million in 2023, then soared by 292.7% to $2.2 billion in 2024, then sank by 80.12% to $432.0 million in 2025, then dropped by 6.5% to $403.9 million in 2026.
- Business Quant data shows BIIB's Payables at $403.9 million in Q2 2026, $358.5 million in Q1 2026, and $432.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 403.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 403.90 Mn |
| Mar 31, 2026 | 358.50 Mn |
| Dec 31, 2025 | 432.00 Mn |
| Sep 30, 2025 | 413.10 Mn |
| Jun 30, 2025 | 408.40 Mn |
| Mar 31, 2025 | 2.14 Bn |
| Dec 31, 2024 | 2.17 Bn |
| Sep 30, 2024 | 2.17 Bn |
| Jun 30, 2024 | 354.50 Mn |
| Mar 31, 2024 | 637.00 Mn |
| Dec 31, 2023 | 553.30 Mn |
| Sep 30, 2023 | 940.10 Mn |
| Jun 30, 2023 | 445.40 Mn |
| Mar 31, 2023 | 491.20 Mn |
| Dec 31, 2022 | 491.50 Mn |
| Sep 30, 2022 | 383.20 Mn |
| Jun 30, 2022 | 1.43 Bn |
| Mar 31, 2022 | 1.40 Bn |
| Dec 31, 2021 | 1.59 Bn |
| Sep 30, 2021 | 1.43 Bn |